biosimilaires de l'EPO (13)
Références
- (1) Société de Néphrologie; Société Francophone de Dialyse; Société de Néphrologie Pédiatrique. Position statement regarding usage of biosimilars: position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique.[Article in English, French]. Nephrol Ther 2006 Dec; 2(7): 432-5.
- (2) guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance : quality issues. CHMP/BWP/49 348/2005
- (3) guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance : non clinical and clinical issues. CHMP/BMWP/42 832/2005
- (4) annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance : non clinical and clinical issues ; guidance on biosimilar medicinal products containing recombinant erythropoietin. CHMP/94 526/2005
- (5) Keithy-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasie due to follow-on epoetin. Kidney Int 2008 Jun 11.
